Tarsus Pharmaceuticals (TARS) Projected to Post Earnings on Thursday

Tarsus Pharmaceuticals (NASDAQ:TARS) will likely be posting its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect the company to announce earnings of ($0.1918) per share and revenue of $169.6770 million for the quarter. Investors can find conference call details on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Wednesday, August 12, 2026 at 4:30 PM ET.

Tarsus Pharmaceuticals (NASDAQ:TARS) last announced its quarterly earnings data on Wednesday, May 6th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.24. Tarsus Pharmaceuticals had a negative return on equity of 14.19% and a negative net margin of 9.02%.The company had revenue of $162.05 million during the quarter, compared to the consensus estimate of $149.60 million. On average, analysts expect Tarsus Pharmaceuticals to post $-1 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Tarsus Pharmaceuticals Price Performance

NASDAQ TARS opened at $61.06 on Tuesday. Tarsus Pharmaceuticals has a 12 month low of $40.55 and a 12 month high of $85.25. The stock has a market cap of $2.63 billion, a price-to-earnings ratio of -54.09 and a beta of 0.53. The company’s 50 day moving average is $61.15 and its two-hundred day moving average is $65.17. The company has a current ratio of 3.74, a quick ratio of 3.71 and a debt-to-equity ratio of 0.21.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the stock. Wall Street Zen lowered shares of Tarsus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. Mizuho lowered their target price on shares of Tarsus Pharmaceuticals from $100.00 to $98.00 and set an “outperform” rating on the stock in a research note on Friday. Oppenheimer started coverage on shares of Tarsus Pharmaceuticals in a report on Friday, April 24th. They issued an “outperform” rating and a $98.00 target price for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a report on Friday, July 17th. Finally, HC Wainwright restated a “buy” rating and issued a $88.00 price objective on shares of Tarsus Pharmaceuticals in a research report on Thursday, July 9th. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $90.17.

Insider Activity at Tarsus Pharmaceuticals

In related news, CEO Bobak R. Azamian sold 10,000 shares of the company’s stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $61.55, for a total transaction of $615,500.00. Following the completion of the transaction, the chief executive officer owned 847,991 shares in the company, valued at approximately $52,193,846.05. This represents a 1.17% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Jeffrey S. Farrow sold 14,396 shares of the firm’s stock in a transaction on Tuesday, June 16th. The shares were sold at an average price of $60.95, for a total transaction of $877,436.20. Following the transaction, the insider directly owned 56,801 shares of the company’s stock, valued at $3,462,020.95. The trade was a 20.22% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders sold 39,850 shares of company stock valued at $2,452,821. Corporate insiders own 9.64% of the company’s stock.

Institutional Trading of Tarsus Pharmaceuticals

Several hedge funds have recently bought and sold shares of the stock. Truvestments Capital LLC increased its holdings in shares of Tarsus Pharmaceuticals by 106.1% in the fourth quarter. Truvestments Capital LLC now owns 909 shares of the company’s stock worth $74,000 after purchasing an additional 468 shares during the last quarter. Osaic Holdings Inc. boosted its stake in Tarsus Pharmaceuticals by 779.1% during the second quarter. Osaic Holdings Inc. now owns 2,778 shares of the company’s stock valued at $113,000 after buying an additional 2,462 shares during the last quarter. Tower Research Capital LLC TRC boosted its stake in Tarsus Pharmaceuticals by 220.3% during the second quarter. Tower Research Capital LLC TRC now owns 4,045 shares of the company’s stock valued at $164,000 after buying an additional 2,782 shares during the last quarter. Mackenzie Financial Corp purchased a new position in Tarsus Pharmaceuticals during the 4th quarter valued at approximately $202,000. Finally, CIBC Private Wealth Group LLC purchased a new position in Tarsus Pharmaceuticals during the 4th quarter valued at approximately $205,000. Hedge funds and other institutional investors own 90.01% of the company’s stock.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.